UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): June 22, 2015

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada (State or Other Jurisdiction of Incorporation) 001-36019 (Commission File Number) 26-1434750 (IRS Employer Identification No.)

509 Madison Avenue, Suite 306, New York, New York 10022 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 980-9155

Copy of correspondence to:

Marc J. Ross, Esq. James M. Turner, Esq. Sichenzia Ross Friedman Ference LLP 61 Broadway New York, New York 10006 Tel: (212) 930-9700 Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On June 22, 2015, Tonix Pharmaceuticals Holding Corp. (the "Company") announced additional non-clinical data from its TNX-201 (dexisometheptene mucate) program presented in two posters entitled "(R)-Isometheptene (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH Increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache" and "The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models" (collectively, the "Posters") at the 57th Annual Scientific Meeting of the American Headache Society in Washington, DC.

The foregoing description of the Posters is qualified in its entirety by reference to the Posters, copies of which are filed as Exhibits 99.01 and 99.02 to, and are incorporated by reference in, this report.

On June 22, 2015, the Company issued a press release announcing the presentation of additional non-clinical data from its TNX-201 (dexisometheptene mucate) program through the Posters. A copy of the press release that discusses this matter is filed as Exhibit 99.03 to, and incorporated by reference in, this report.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits.
 - 99.01 (R)-Isometheptene (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH Increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache Poster
 - 99.02 The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models Poster
 - 99.03 Press Release, dated June 22, 2015, issued by Tonix Pharmaceuticals Holding Corp.

2

SIGNATURE


Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING CORP.

By: <u>/s/ LELAND GERSHELL</u> Leland Gershell Chief Financial Officer

Date: June 22, 2015

Exhibit 99.01



The (R)- isomer of isometheptene*, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models. Jefferson Nathan T. Fried ¹, Michael L. Oshinsky¹, Bruce Daugherty², Seth Lederman² and Melanie B. Elliott¹ 1 Department of Neurosurgery, Thomas Jefferson University, Philadelphia, PA, USA 2 Tonix Pharmaceuticals Holding Corp, NYC, NY, USA melanie.elliott@jefferson.edu Abstract **Results - Inflammatory Soup Model Results - STA Model** Figure 1: Trigemini flammatory soup n Figure 5: Effects of 1mg/kg of R- & S- enantiomers of isometheptene on trigeminal sensitivity in the STA model. ptene, a race 1.5 chronic migraine hav nisms behind migrain 3x/wk for a month wh trigeminal allodynia (manipulation. Both th trigeminal sensitivity, migraine triggers. IS (n=10) 3 ions of IS "tran te, as seen as 1 Threshold (g) ---- Ghroni Propertions + + Objective: The aim of this study was to test the effects of the (R)- and (S) inflammtory soup and the spontaneous trigeminal allodvnia rat 8 9 fusions 2.5 ~nt (hr) 21 36 Days Days Later Later 1.5 3.5 24 0.5 Methods: The pharmacokinetics (PK) of racemic and fects of the (R)- and (S)- isometheptene or for this study represent the 17th generation ments were obtained to determine trigemics ment with (S)-isometheptene, (R)-isomethe Arat colony. Periorbital thresholds, as measured with von Frey fla-ity prior to and 0.5 hr-, 1.5 hr-, 2.5 hr-, 3.5 hr-, and 24 hr-post treat-saline vehicle. All treatments were administered intraperitoneally. Figure 6: R- & S- El isomethe I4 Fileshold Threshold tene on triger of (R)-SomeHigtere had small Private group, we make a probability of the (R)-SomeHigter had the result of the res mucate signifi (1.7-fold) time Change in 1 fold) time p sensitivity in (Fig. 2 & 5). s were trea oportional models, two models representative of the chroni nine the dose response of this effect. These find 2.5 Treast (hi) 1.5 Time Perof migra 2.5 1.5 Summary Introduction f R- & S Proportional Change in Threshold flammatory soup these changes. -The (S) is that the (R)--These results suggest that Citations -Zhang L, Zhao TY, Hou N, Teng Y, Cheng X, War Generation and primary phenotypes of imidazolin mice. CNS Neurosci Ther. (2013) 19(12):978-81. 1.5 2.5 ng B, Ch en Y, Jiang L, Wu N, Su ng X, Li J -Oshinsky ML, Gomonchareonsiri S. Episodic headache. Headache. (2007) 47(7):1026-36. **Results - STA Model** -Oshinsky ML, Menka M, Sanghvi MS, Maxwell CR, Gonzalez D, Spangenberg R, Cooper M, and Silberstein S. Spontaneous Trigeminal Allodynia in Rats: A Model of Primary Headache. Headache (2012) 52(9) 1336–1349. . Funding s Holding Corp, NYC, NY, USA -Tonix Pharmaceutic -Mentoring Junior In Prind, NT, Cahinaky, MI, Daugherty, BL Lederman S and Elliott, MB. The (R) forder, NT, Cahinaky, MI, Daugherty, BL Lederman S and Elliott, MB. The (R) isomer of isomethrepiene decreases trigenmate small/wity in a rat model of pri-mary headinghies. Fieldanches 2015. June 5(5) Abstract Fields 1988. 184. Mais alodyris trat Mais ro trait Commit alodyris trat

Tonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society

- TNX-201 demonstrates significant analgesic effects in animal models of migraine and chronic pain -

- TNX-201 targets the imidazoline-1 receptor and may represent a novel approach to the treatment of pain -

NEW YORK – June 22, 2015 – <u>Tonix Pharmaceuticals Holding Corp.</u> (Nasdaq:TNXP) ("Tonix"), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, announced that it presented non-clinical data from its TNX-201 (dexisometheptene mucate) program in two posters at the 57th Annual Scientific Meeting of the American Headache Society in Washington, DC. Tonix is currently evaluating TNX-201 in a Phase 2 proof-of-concept (POC) study in episodic tension-type headache. To learn more, please visit <u>www.clinicaltrials.gov</u> (NCT02423408).

The active ingredient in TNX-201, dexisometheptene mucate, contains (R)-isometheptene, or (R)-IMH, a single optical isomer of isometheptene. Racemic IMH, a mixture of both the (R) and (S) isomers, had been widely used as a single-agent prescription medicine and as a component of combination drug products (e.g., Midrin[®]) for many decades in the U.S. for various indications including tension-type headache. IMH was introduced as a pharmaceutical prior to 1962, and no products containing IMH are currently approved by the U.S. Food and Drug Administration (FDA) for any indication. TNX-201 is being developed as a new chemical entity for the treatment of episodic tension-type headache, based on current FDA drug registration requirements.

The two posters are summarized below, and are available on Tonix's website at www.tonixpharma.com.

Abstract PS29. "(*R*)-Isometheptene (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH Increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache" ($^{(1)}$)

Key points:

- Data from receptor binding studies, taken together with the recent description of a decreased pain threshold in imidazoline-1 receptor (I₁R) knock-out mice⁽²⁾, suggest that I₁R may be the primary site of action for racemic IMH's analgesic effects. Since (R)-IMH, the active ingredient in TNX-201, binds I₁R with approximately 60-fold greater affinity than (S)-IMH, TNX-201 may be responsible for the therapeutic effect of racemic IMH.
- · In anesthetized rats, treatment with (S)-IMH resulted in dose-dependent and statistically-significant blood pressure increases that were higher relative to those produced by the (R)-isomer.

Abstract PS58. "The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models" $^{(3)}$

Key points:

- The effects of (R)-IMH and (S)-IMH were evaluated in two rat models of trigeminal pain which feature aspects of chronic migraine: the Inflammatory Soup (IS) model and the Spontaneous Trigeminal Allodynia (STA) model. ^(4,5) These models had been developed to allow for the testing of therapeutic compounds for migraine. Both of these models experience similar symptoms to human migraine patients such as episodic or chronic trigeminal hypersensitivity, phonophobia, responsiveness to abortive and prophylactic headache treatments, and sensitivity to migraine triggers.
- In the IS model, treatment with 30 mg/kg of (R)-IMH mucate significantly increased trigeminal thresholds at each of the 0.5 hour (hr) (2.3-fold, p<0.01), 1.5 hr (3.0-fold, p<0.01), 2.5 hr (2.9-fold, p<0.001), and 3.5 hr (1.7-fold, p<0.05) time points.
- In the STA model, treatment with 30 mg/kg of (R)-IMH mucate significantly increased trigeminal thresholds at the 0.5 hr (7.8-fold, p<0.01), 1.5 hr (4.3-fold, p<0.05), 2.5 hr (4.5-fold, p<0.01), 3.5 hr (8.5-fold, p<0.01), and 24 hr (8.2-fold, p<0.01) time points.
- · Treatment with 30 mg/kg of (S)-IMH mucate had no effect on trigeminal sensitivity in either the IS or STA models.

"Our findings that TNX-201 selectively modulates a receptor in the central nervous system that appears to regulate pain perception and responses, together with positive data in two rodent models representative of migraine, support the development of TNX-201 as a therapeutic for headache and potentially other pain indications and one that may be differentiated from currently-approved products," said Bruce Daugherty, Ph.D., Tonix's chief scientific officer. "We look forward to reporting the results of our Phase 2 POC study in episodic tension-type headache in the fourth quarter of this year."

References

- (1) Daugherty BL, Gershell L, and Lederman S. (R)-isometheptene (IMH) binds to the imidazoline-1 receptor and (S)-isometheptene increases blood pressure: potentially superior benefit to risk ratio for (R)-IMH as an analgesic for headache. Headache 2015;June 55(53):Abstract PS29. 172.
- (2) Zhang L et al. CNS Neurosci Ther 2013;19:978-81.
- (3) Fried NT, Oshinsky MI, Daugherty BL, Lederman S and Elliott MB. The (R) isomer of isometheptene decreases trigeminal sensitivity in a rat model of primary headache. Headache 2015;June 55(53):Abstract PS58. 184.
- (4) Oshinsky ML and Gomonchareonsiri S. Headache 2007;47:1026-36.
- (5) Oshinsky ML et al. Headache 2012;52:1336-1349.

About Episodic Tension-Type Headache

<u>Episodic tension-type headache</u> is the most common type of headache. It is estimated that approximately 30% of U.S. adults experience frequent episodic tension-type headaches (one to 15 headaches per month over a three-month period). Tension-type headache pain is often described as a constant pressure on both sides of the head, and typically lasts for several hours. All of the FDA-approved prescription options for tension-type headache contain barbiturates.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is dedicated to the development of next-generation medicines for common yet challenging disorders of the central nervous system, characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's Tonmya[™] is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia. TNX-102 SL, the same proprietary product candidate as Tonmya, is currently being evaluated in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 in episodic tension-type headache is ongoing. This press release and further information about Tonix can be found at <u>www.tonixpharma.com</u>.

TNX-102 SL and TNX-201 are Investigational New Drugs and have not been approved for any indications.

Cautionary Note on Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on February 27, 2015 and future periodic reports filed with the Securities and Exchange Commission. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

Contacts:

Tonix Pharmaceuticals Holding Corp. Leland Gershell Chief Financial Officer (212) 980-9155 x104 leland.gershell@tonixpharma.com

Martini Communications Amy Martini (investors) amartini@martinicommunications.com

Dian Griesel Int'l. Susan Forman/Laura Radocaj (media) (212) 825-3210 <u>sforman@dgicomm.com</u> <u>lradocaj@dgicomm.com</u>